NYSE:ABT - New York Stock Exchange, Inc. - US0028241000 - Common Stock - Currency: USD
ABBOTT LABORATORIES
NYSE:ABT (1/27/2025, 11:44:07 AM)
128.86
+3.83 (+3.06%)
The current stock price of ABT is 128.86 USD. In the past month the price increased by 9.38%. In the past year, price increased by 11.62%.
These S&P500 stocks are moving in today's session
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Cramer takes a look at TETRA Technologies, Abbott, Wendy's, Nu Holdings and Casella Waste on the latest edition of "Mad Money."
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ISRG | INTUITIVE SURGICAL INC | 78.05 | 203.77B | ||
SYK | STRYKER CORP | 34.07 | 151.19B | ||
BSX | BOSTON SCIENTIFIC CORP | 42.84 | 149.02B | ||
MDT | MEDTRONIC PLC | 17.43 | 117.32B | ||
BDX | BECTON DICKINSON AND CO | 18.75 | 71.55B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 21.09 | 40.66B | ||
EW | EDWARDS LIFESCIENCES CORP | 25.66 | 40.41B | ||
RMD | RESMED INC | 30.91 | 37.61B | ||
IDXX | IDEXX LABORATORIES INC | 38.97 | 34.94B | ||
DXCM | DEXCOM INC | 51.82 | 34.41B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.15 | 25.57B | ||
ZBH | ZIMMER BIOMET HOLDINGS INC | 14.14 | 22.20B |
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 114,000 full-time employees. The firm is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The firm operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
ABBOTT LABORATORIES
100 Abbott Park Road, Abbot Park
ABBOTT PARK ILLINOIS 60064 US
CEO: Robert B. Ford
Employees: 114000
Company Website: https://www.abbott.com
Investor Relations: https://www.abbott.com/investors.html
Phone: 12246676100
The current stock price of ABT is 128.86 USD.
The exchange symbol of ABBOTT LABORATORIES is ABT and it is listed on the New York Stock Exchange, Inc. exchange.
ABT stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ABT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ABT.
ABT has a dividend yield of 1.89%. The yearly dividend amount is currently 2.05.
The PE ratio for ABT is 27.59. This is based on the reported non-GAAP earnings per share of 4.67 and the current share price of 128.86 USD.
The outstanding short interest for ABT is 0.83% of its float.
ChartMill assigns a technical rating of 6 / 10 to ABT. When comparing the yearly performance of all stocks, ABT turns out to be only a medium performer in the overall market: it outperformed 68.45% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to ABT. ABT has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months ABT reported a non-GAAP Earnings per Share(EPS) of 4.67. The EPS increased by 5.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 13.99% | ||
ROA | 7.76% | ||
ROE | 14.49% | ||
Debt/Equity | 0.32 |
ChartMill assigns a Buy % Consensus number of 81% to ABT. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 11.61% and a revenue growth 7.06% for ABT